

Invictus Therapeutics Ltd Change of Registered Office

Sydney, New South Wales, 12 December 2025 – The Directors of Invictus Therapeutics Ltd (the **Company** or **VTL**) wish to advise that the Company, and its subsidiaries, have changed the address of the registered office and principal place of business to:

c/- Structured Tax & Accounting
Suite 2, 24 Birdwood Lane,
Lane Cove, NSW 2066

This announcement was authorised for release by the Company Secretary.

For more information please contact:

Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Catriona Glover, Company Secretary
Tel: +61 (0) 402 328 200

About Invictus Therapeutics Ltd

Invictus Therapeutics Ltd (formerly VGI Health Technology Limited (NSX:VTL)) is an Australian public listed biotechnology company developing and commercialising prescription medicines and novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD), Metabolic dysfunction-Associated Steatohepatitis (MASH), pancreatic adenocarcinoma (pancreatic cancer), hyperlipidaemia, hypertension and diabetes. Invictus owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a clinical development program for prescription medicines and a product development program for evidence-based nutraceuticals.